References
-
1
Seeger H, Wallwiener D, Mueck A O.
The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells.
Horm Metab Res..
2003;
35
76-80
-
2
Writing group for Women’s Health Initiative Investigators .
Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative Randomized controlled trial.
JAMA.
2002;
288
321-333
-
3
Million Women Study Collaborators .
Breast cancer and hormone-replacement therapy in the Million Women Study.
The Lancet.
2003;
362
419-427
-
4
Catherino W H, Jordan V C.
Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity.
J Steroid Biochem Mol Biol..
1995;
55
239-246
-
5
Shields-Botella J, Duc I, Duranti E, Puccio F, Bonnet P, Delansorne R, Paris J.
An overview of nomegestrol acetate selective receptor binding and lack of estrogenic action on hormone-dependent cancer cells.
J Steroid Biochem Mol Biol.
2003;
87(2-3)
111-122
-
6
Schoonen W GEJ, Joosten J WH, Kloosterboer H J.
Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines.
J Steroid Biochem Mol Biol.
1995;
55
423-437
-
7
Schoonen W GEJ, Joosten J WH, Kloosterboer H J.
Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines.
J Steroid Biochem Mol Biol.
1995;
55
439-444
-
8
Botella J, Duranti E, Duc I, Cognet A M, Delansorne R, Paris J.
Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells.
J Steroid Biochem Mol Biol.
1994;
50
41-47
-
9
Larrea F, García-Becerra R, Lemus A E, García G A, Pérez-Palacios G, Jackson K J, Coleman K M, Dace R, Smith C L, Cooney A J.
A-Ring Reduced Metabolites of 19-nor Synthetic Progestins as Subtype Selective Agonists for ER.
Endocrinology.
2001;
142
3791-3799
-
10
Tong W, Perkins E, Xing L, Welsh W J, Sheehan D M.
QSAR models for binding of estrogenic compounds to estrogen receptor α and ß subtypes.
Endocrinology.
1997;
138
4022-4025
J. Shields-Botella
In Vitro Pharmacology
Preclinical R&D-Biology · Théramex · 6 avenue Prince Héréditaire Albert · 98000 Monaco
Telefon: +377(92)050870
Fax: +377(92)050881
eMail: jshields@theramex.mc.
